Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hunting the quiet phase of a Mosquito-Borne virus before the next outbreak

NCT ID NCT05139524

Knowledge-focused Sponsor: Washington State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 05, 2026 · Last updated Oct 06, 2026 · Updated 1 time

Summary

Rift Valley fever spreads from livestock such as cattle, sheep, goats, and camels to people, and East and Central Africa have seen more than 15 major epidemics in 50 years. Researchers are studying hotspots in Kenya, Uganda, Tanzania, and the Democratic Republic of Congo to measure how much the virus circulates in people, livestock, and wildlife between outbreaks. They test blood samples for signs of past or recent infection, including viral RNA and antibodies. The goal is to understand the true burden of the disease and spot other undetected infections, which could support an early warning system and vaccination planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the team maps where the virus circulates between outbreaks, health officials could build an early warning system and target vaccination when risk rises.
What could go wrong
This is an observational study, so it cannot prove that any warning system or vaccine will work. Findings from four countries may not apply everywhere, and many fever cases will turn out to have other causes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For health facility based study: Patients attending enrolled health facilities in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania). For community cross sectional survey: Residents of households in study areas i.e. North and South Kivu (DRC), Isingiro, Rubanda and Kabale districts (Uganda), Muranga, Isiolo, Tana River and Marsabit counties (Kenya) and Iringa district (Tanzania).

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for health facility based study: Category A: A sample of patients presenting to the health facility meeting this inclusion criteria will be enrolled: • Persons ≥ 10 years of age who are malaria negative AND have undifferentiated acute fever at the time of presentation (≥ 37.5°C) or reported fever in the past 4 weeks. Category B: A sample of patients presenting to the health facility meeting this inclusion criteria will be enrolled: • Persons ≥ 10 years of age who are malaria positive AND have undifferentiated acute fever at the time of presentation (≥ 37.5°C) or reported fever in the past 4 weeks. Category C: All patients at the health facility meeting these criteria will be enrolled in the study Persons ≥ 10 years of age with: • Unexplained bleeding with or without fever manifesting as either: Blood in vomitus, Bleeding from the gums, Bleeding from the nose, Bleeding in the eyes (red eyes), Non-menstrual genital bleeding, Bleeding from any other body site OR • Infectious disease illness of unknown etiology requiring hospitalization. The illness should not be responding to antimalarials and/or antibiotics following 7 days of treatment Inclusion Criteria for community cross sectional study: Member of household 2 or more years of age. Exclusion Criteria: Those who do not consent or refuse written consent. If a participant is severely ill and has no next of kin to provide consent +/- witness on their behalf. If a participant is known to have blood clotting disorders, allergies arising from injections, or if a participant has ever fainted during previous injections or blood collection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemorrhagic fevers, viral are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Communicable Diseases, Emerging Rift valley fever viral hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemorrhagic fevers, viral Rift valley fever

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Iringa

    NOT_YET_RECRUITING

    Iringa, Tanzania

  • Isiolo county

    NOT_YET_RECRUITING

    Isiolo, Kenya

  • Kabale Regional Referral Hospital & Kabale district

    RECRUITING

    Kabale, Uganda

  • Marsabit county

    NOT_YET_RECRUITING

    Marsabit, Kenya

  • Muranga county

    RECRUITING

    Murang’a, Kenya

  • Rwekubbo health centre IV & Isingiro district

    RECRUITING

    Isingiro, Uganda

  • Rwekubo Health Centre IV & Rubanda district

    RECRUITING

    Rubanda, Uganda

  • South Kivu

    NOT_YET_RECRUITING

    Bukavu, Democratic Republic of the Congo

  • Tana River County

    NOT_YET_RECRUITING

    Hola, Kenya

  • Virunga Hospital & North Kivu

    RECRUITING

    Goma, North Kivu, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.